IL33 and allergic disease: Previous studies have demonstrated that blocking the interaction of IL-33/ST2 alleviates the severity of allergic disease by reducing Th2 cytokine production, eosinophilic inflammation, serum IgE level, and airway hyper­reactivity [22-25].